Citius Oncology Inc (CTOR)

$0.73 +0.09 (13.73%)
Market Cap 45.87M
Revenue (ttm) 0.00
Net Income (ttm) -21.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.16
Volume 180,200
Avg Vol 1,592,158
Day's Range N/A - N/A
Shares Out 71.55M
Stochastic %K 88%
Beta -0.19
Analysts Strong Sell
Price Target $3.00

Latest News on CTOR

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Feb 14, 2025, 4:30 PM EST - 2 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CTXR

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Feb 14, 2025, 4:30 PM EST - 2 months ago

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Feb 6, 2025, 8:55 AM EST - 2 months ago

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

CTXR

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Jan 7, 2025, 8:08 AM EST - 3 months ago

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

CTXR

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Jan 6, 2025, 7:50 AM EST - 3 months ago

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

CTXR

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Dec 27, 2024, 5:00 PM EST - 4 months ago

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update